Previous 10 | Next 10 |
home / stock / clxpf / clxpf news
A clinical trial whose results were published last week has found that psilocybin may be used to treat depression. The phase 2 study was the first randomized trial that compared the effectiveness of commonly prescribed antidepressants with therapeutic doses of psilocybin. Its findings we...
A study conducted recently proposes that psychedelic-assisted therapy using MDMA to help treat PTSD is not as efficacious among individuals who have recently used psychiatric drugs commonly prescribed by doctors, known as selective serotonin re-uptake inhibitors. The research findings were...
Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, has selected alcohol use disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. In the announcement, the compan...
Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has selected Alcohol Use Disorder (“AUD”) as the initial targe...
In recent years, microdosing has become popular as a wellness trend, both in the United States as well as overseas in countries such as Australia. Microdosing involves consuming a low dose of a psychedelic drug to reduce anxiety and stress or boost performance. While there have been ...
Palm Beach, FL – April 21, 2021 – The psychedelics industry has entered the spotlight! The rapidly increasing acceptance of psychedelic treatments is creating a strong demand from therapists and patients for access to the new products and therapies. Industry reports for ...
Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has successfully demonstrated Proof of Concept for its deuterated tryptamine...
Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, has announced the formation of its clinical advisory board. Additions to the board include Maurizio Fava, MD, psychiatrist-in-chief in the Department of Psychiatry at Massachusetts Ge...
Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Bloom Burton ...
This is Psychedellux – the week’s top business news in the psychedelics industry. Cybin said it was Starting the IND-enabling trials for CYB003 and CYB004 which is a step forward for Cybin to study these molecules. Our team hopes to produce a robust submission to the FDA t...
News, Short Squeeze, Breakout and More Instantly...
Canadian Lynx Pete Ltd Company Name:
CLXPF Stock Symbol:
OTCMKTS Market:
Canadian Lynx Pete Ltd Website:
NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announces the availability of a broadcast titled, “Psychedelic Therapies Offer Hope for Mental Health.” To hear the AudioPressRelease, please vi...
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (...
Last week, legislators in Massachusetts heard testimony about legislation that would establish a task force that would look into the consequences of legalizing psychedelic substances such as ayahuasca and psilocybin. The legislation was introduced by Rep. Mike Connolly, and while membe...